Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Status:
RECRUITING
Trial end date:
2027-05-30
Target enrollment:
Participant gender:
Summary
The goal of this study is to learn the efficacy and safety of nimotuzumab combined with toripalimab and gemcitabine/cisplatin regimen treatment recurrent/distant-metastasis nasopharyngeal carcinoma.
Phase:
PHASE2
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences